Cisapride ® is rapidly absorbed from the gastrointestinal tract and reaches maximum plasma concentrations of 1.0 to 1.5 hours of oral administration, bioavailability is 40 to 50%. The maximum concentration of cisapride was detected at the liver and gastrointestinal tract. The elimination half-life is 8 to 10 hours Cisapride is excreted as metabolites in urine and feces. Cisapride ® 98% is bound to plasma proteins. Cisapride is a prokinetic agent that increases or restores motility of the gastrointestinal tract, which acts on the plexuses mientéricos, increasing the physiological release of acetylcholine. In general, when Cisapride is administered as single doses or repeated increases in 20 to 50% of the esophageal sphincter pressure. It has been observed that the administration of Cisapride accelerates gastric emptying in patients enrolled with motility disorders, including those with idiopathic gastroparesis, diabetic and post surgical. Cisapride enhances antral and duodenal motility, and decreases by up to three times the volume needed to antral stimulation. The transit of the small intestine and colon were increased with administration of single doses of Cisapride. There is a clear dose-response relationship at different levels: gastroesophageal, small bowel and colon.
There are no additional images for this product.